Fredag 7 November | 10:47:06 Europe / Stockholm

Kalender

Est. tid*
2026-02-05 08:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
2025-10-06 16:12:46
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 October 2025 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcome of the exercise of warrants of series TO 11, which were issued in connection with the Company's rights issue of units in 2024. In total, 28,522,440 warrants of series TO 11 were exercised, corresponding to approximately 88.5 percent of the total number of outstanding warrants of series TO 11, for subscription of 713,061 shares at an exercise price of SEK 14,65 per share. ExpreS2ion will receive approximately SEK 10.4 million before issue costs through the exercise of the warrants of series TO 11. Guarantee commitments of 92,480 shares, corresponding to approximately 11.5 percent of the outstanding warrants of series TO 11, will thus be utilised. The Board of Directors has therefore resolved on a directed issue of 92,480 new shares (the "Directed Issue") to the guarantors Nils Berg, UBB Consulting AB, John Moll, Elvil AB, Paginera Invest AB and Peter Nilsson (the "Guarantors"). Through the exercise of the warrants of series TO 11 and the Directed Issue, the Company will receive approximately SEK 11.8 million before transaction costs. Furthermore, the Board of Directors has resolved on a set-off issue of 66,346 new shares to the Guarantors to pay the guarantee compensation (the "Compensation Issue" and, together with the Directed Issue, the "New Issues").

Bent U. Frandsen, CEO, comments:
“Amid tough biotech markets, our investors and guarantors rallied behind ExpreS2ion. Their strong support — even before guarantees — shows clear belief in our lead breast cancer vaccine ES2B-C001, now in Phase I trials, our broader immunotherapy pipeline, and our clinically validated ExpreS2™ platform. We thank all shareholders and guarantors for ensuring full subscription. This vote of confidence strengthens our position as we continue advancing our programs and seeking the resources needed to bring innovative vaccines to patients.

Background
ExpreS2ion completed a rights issue of units during the third quarter of 2024. Within the scope of the rights issue, ExpreS2ion issued a total of 32,221,672 warrants of series TO 11, of which 30,046,672 warrants of series TO 11 were issued as a result of the rights issue, and an additional 2,175,000 warrants of series TO 11 were issued to rights issue guarantors who chose to receive guarantee compensation in units.

Prior to recalculation of the warrants of series TO 11, one (1) warrant of series TO 11 gave the owner the right to subscribe for one (1) new share in the Company. Following the recalculation of the warrants, forty (40) warrants of series TO 11 gave the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 11 was defined as 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from 1 September 2025 to 12 September 2025, but not less than the share's quota value (SEK 4.444444) and not more than SEK 70 (previously SEK 1.75) per share (following recalculation). During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 20.94, therefore the exercise price for the warrants of series TO 11 was set to SEK 14.65.

Outcome
In total, 28,522,440 warrants of series TO 11 were exercised, corresponding to approximately 88.5 percent of the total number of outstanding warrants of series TO 11, for subscription of 713,061 shares at an exercise price of SEK 14,65 per share. ExpreS2ion will receive approximately SEK 10.4 million before issue costs through the exercise of the warrants of series TO 11. Guarantee commitments of 92,480 shares, corresponding to approximately 11.5 percent of the outstanding warrants of series TO 11, will thus be utilised. The Board of Directors has therefore resolved on the Directed Issue of 92,480 new shares to the Guarantors Nils Berg, UBB Consulting AB, John Moll, Elvil AB, Paginera Invest AB and Peter Nilsson. Through the exercise of the warrants of series TO 11 and the Directed Issue, the Company will receive approximately SEK 11.8 million before transaction costs.

For the guarantee commitments, a guarantee compensation of thirteen and a half (13.5) percent of the guaranteed amount is paid in the form of newly issued shares in the Company. The Board of Directors has therefore today resolved on the Compensation Issue of 66,346 shares to pay the guarantee compensation.

Exercised warrants of series TO 11 have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately two weeks.

The Board of Directors' resolutions on the New Issues
It is the Board of Directors' assessment that it was in the interest of both the Company and its shareholders to ensure full exercise of the warrants of series TO 11 and, to carry out the Directed Issue. The guarantee commitments and the Directed Issue enable the Company to raise additional capital at a low cost, time-efficiently, and with less complexity than other forms of capital raising and financing alternatives. Holders of warrants of series TO 11 hade the possibility to exercise the warrants for subscription of new shares in the Company, thereby limiting the number of shares in the Directed Issue. It is the Board of Directors' overall assessment that the reasons for ensuring full exercise of the warrants of series TO 11 and carrying out the Directed Issue with deviation from shareholders' preferential rights with sufficient strength outweigh the reasons supporting the main rule that issues should be carried out with preferential rights for the shareholders.

The reason for deviating from the shareholders' preferential rights in the Compensation Issue is to fulfil the Company's obligations to the Guarantors as a result of the guarantee commitments entered into. The Board of Directors also considers that it is in favour of the Company's financial position and in the interest of the shareholders to pay the guarantee compensation in the form of newly issued shares instead of cash payment as it releases funds that strengthen the Company's working capital.

The subscription price in the New Issues corresponds to the subscription price upon exercise of warrants of series TO 11. The subscription price in the New Issues has been determined through arm's length negotiations with the Guarantors, in consultation with financial advisors and by analysing a number of market factors such as the Company's financing needs, alternative cost of other financing and assessed market interest for an investment in the Company. It is the Board of Directors' assessment, based on the above factors, that the subscription price in the New Issues reflects current market conditions and current demand. Against this background, the Board of Directors considers the subscription price to be on market terms.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO 11 and the New Issues, the number of shares in ExpreS2ion increase by 871,887 shares to a total of 3,530,233 shares. The share capital will increase by SEK 3,875,053.340364 to SEK 15,689,924.472912.

For existing shareholders who did not exercise any warrants of series TO 11, the dilution amounts to approximately 24.7 percent based on the number of shares following exercise of the warrants of series TO 11 and the New Issues.

Advisors
Vator Securities act as financial advisor and issuing agent to the Company in connection with the transaction. Advokatfirman Schjødt is the Company's legal advisor in connection with the transaction.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB